MedTrace Logo

Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer

NCT00028860 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-07-10

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy following surgery in treating patients who have urinary tract cancer.

Conditions

  • Bladder Cancer
  • Transitional Cell Cancer of the Renal Pelvis and Ureter

Interventions

BIOLOGICAL

filgrastim

DRUG

carboplatin

DRUG

gemcitabine hydrochloride

DRUG

ifosfamide

DRUG

paclitaxel

PROCEDURE

adjuvant therapy

Sponsors & Collaborators

  • Tulane University Health Sciences Center

    lead OTHER

Principal Investigators

  • Raja Mudad, MD, FACP · Tulane University Health Sciences Center

Study Design

Purpose
TREATMENT

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-10-31
Completion
2004-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00028860 on ClinicalTrials.gov